Research
Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses
Nature · By Dylan Kwart ·
The Brief
- A study published in Nature Communications on 15 November 2026 reports that cytotoxic drugs and bispecific T cell engagers act synergistically.
- The authors report that the combination rewires host immunity and elicits polyclonal antitumor T cell responses.
- The work focuses on TAA×CD28 costimulatory bispecific antibodies, which crosslink CD28 on T cells to a tumor-associated antigen to provide tumor-targeted costimulation.
Why it matters
It suggests that combining established cytotoxic drugs with bispecific T cell engagers could broaden antitumour T cell responses, which may inform how cancer immunotherapies are combined.
Who’s affected
- cancer immunologists
- oncology researchers
- #cancer immunotherapy
- #t cells
- #bispecific antibodies
- #cytotoxic drugs
- #costimulation
Nature Communications, Published online: 15 November 2026; doi:10.1038/s41467-026-79192-3 TAA×CD28 costimulatory bispecific antibodies are a class of immunotherapeutics that provide tumor-targeted CD28 costimulation to T cells by crosslinking CD28 on T cells to a tumor-associated…
Timeline
Study published online in Nature Communications
nature.com
Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses